Psych Vivas · General adult psychiatry — anxiety disorders
Panic disorder and agoraphobia — structured clinical viva
Fellowship viva covering severe panic with agoraphobia, pseudo-resistance, SSRI re-trial dosing, CBT exposure, benzodiazepine discontinuation with CBT, and inappropriate ECT expectations.
On this page & tools
Target exams
Interpretation
Reveal interpretation
This is severe panic disorder with agoraphobia and chronic benzodiazepine use, with pseudo-resistance to an inadequate SSRI trial (50 mg for only 10 days — neither dose nor duration sufficient, and early activation may have been mislabelled as failure). ECT is not indicated for uncomplicated panic/agoraphobia and should be gently corrected if the partner equates it with "stronger treatment for anxiety."[1][4]
Formulation. Vulnerability (anxiety sensitivity), precipitants (first unexpected attacks), maintaining factors (avoidance, safety behaviours, diazepam as safety signal, no exposure therapy), and functional collapse (housebound). Assess depression/suicide risk, substances, and medical differentials as always.[4]
Plan. Collaborative psychoeducation; high-quality CBT with interoceptive and graded situational exposure (home-based/outreach if needed initially); restart SSRI carefully — e.g. sertraline 25 mg then 50 mg with slow titration toward a therapeutic range with early review for activation; do not escalate to "stronger tranquilisers" as definitive care.[1][3][4]
Benzodiazepine. Agree a slow supervised taper, convert to a longer-acting agent if appropriate under local practice, and pair with CBT techniques shown to aid benzodiazepine discontinuation in panic.[2]
Communication. Empathise with the partner's desperation; explain evidence hierarchy (CBT + SSRI/SNRI); set functional goals (leaving house, short trips); book early review; safety-net depression/suicide.[4]
Key points
[1] [2] [3]References
- [1]Barlow DH, Gorman JM, Shear MK, Woods SW Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial JAMA, 2000.PMID 10815116
- [2]Otto MW, Pollack MH, Sachs GS, et al. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder Am J Psychiatry, 1993.PMID 8379551
- [3]Pollack MH, Otto MW, Worthington JJ, et al. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial Arch Gen Psychiatry, 1998.PMID 9819070
- [4]Bandelow B, Michaelis S, Wedekind D Treatment of anxiety disorders Dialogues Clin Neurosci, 2017.PMID 28867934